Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug combo study halted after just 3 patients

NCT ID NCT03993379

Disease control Sponsor: CytomX Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called CX-072 combined with other cancer treatments for adults with solid tumors or advanced melanoma. The goal was to see if the combination could shrink tumors. However, the study was stopped early and only 3 people took part, so we don't have enough information to know if it works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

3 people

The number who actually took part.

Started

Nov 2019

Finished

May 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. At least 18 years of age 2. Measurable disease as defined by RECIST v1.1 3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 4. Agree to provide tumor tissue and blood samples for biomarker assessment Exclusion Criteria: 1. Treatment with cytotoxic chemotherapy, biologic agents, radiation, immunotherapy, or any investigational agent within 28 days prior to the first dose of study treatment. 2. Prior therapy with a chimeric antigen receptor T cell-containing regimen 3. History of active autoimmune disease(s) including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies, type 1 insulin-dependent diabetes mellitus 4. History of myocarditis regardless of the cause 5. History of intolerance to prior checkpoint inhibitor therapy defined as the need to discontinue treatment due to an irAE 6. History of any syndrome or medical condition that required treatment with systemic steroids (≥10 mg daily prednisone equivalents) or immunosuppressive medications. 7. History of severe allergic or anaphylactic reactions to human mAb therapy or known hypersensitivity to any Probody therapeutic

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma neoplasm Recurrence type 1 diabetes mellitus 12

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor Unresectable or metastatic melanoma

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, South Korea

  • Ballarat Oncology and Haematology Services

    Wendouree, Victoria, Australia

  • Beacon Cancer Care

    Coeur d'Alene, Idaho, 83814, United States

  • City of Hope National Medical Center

    Duarte, California, 91010, United States

  • Clinica Universitaria de Navarra

    Pamplona, Spain

  • Columbia Medical Center

    New York, New York, 10032, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Hospital Clinic de Barcelona. Servicio Oncologia Medica

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • ICO Hospitalet, Hospital Duran I Reynals

    Barcelona, 08908, Spain

  • Inova Dwight and March Schar Cancer Institute

    Fairfax, Virginia, 22031, United States

  • Multicare Institute for Research and Innovation

    Spokane, Washington, 99204, United States

  • NYC Cancer Institute

    New York, New York, 10016, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40202, United States

  • Oregon Health & Science Center

    Portland, Oregon, 97210, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • START- Madrid

    Madrid, Spain

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Sunshine Coast University Private Hospital

    Sunshine Coast, Queensland, Australia

  • The Angeles Clinic and Research Institute

    Los Angeles, California, 90025, United States

  • The Netherlands Cancer Institute

    Amsterdam, Netherlands

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • University Medical Center Groningen

    Groningen, Netherlands

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • Virginia Cancer Specialists

    Fairfax, Virginia, 22031, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.